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50-WORD ABSTRACT 
Targeted electrical energy applied to wounds has been shown to improve wound-healing 
rates. However, the mechanisms are poorly understood. We show that electrical energy 
stimulation applied continuously for 48 hours to the skin of healthy patients has the effect of 
modifying gene expression in a number of identified genes. 
 
ABSTRACT 
Objective Targeted electrical energy applied to wounds have been shown to improve wound-
healing rates. However, the mechanisms are poorly understood. The aim of this study was to 
identify genes that are responsive to electrical stimulation (ES) in healthy subjects with 
undamaged skin. 
Approach To achieve this objective we used a small non-invasive, ES medical device to 
deliver a continuous specific set sequence of electrical energy impulses over a 48-hour period 
to the skin of healthy volunteers and compared gene expression by microarray analysis. 
Results Application of this specific electrical impulse resulted in differential expression of 105 
genes, the majority of which were downregulated. Our post-microarray analyses revealed 
there was commonality with a small number of genes that have previously been shown to be 
upregulated in skin wounds including venous leg ulcers. 
Innovation  
The identification of the differential expression in this subset of genes in healthy subjects 
provides new potential lines of scientific enquiry for identifying similar responses in subjects 
with slow or poorly healing wounds. 
Conclusion  
The specific sequence of electrical energy stimulation applied continuously for 48 hours to the 
skin of healthy patients has the effect of modifying gene expression in a number of identified 
genes. 
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INTRODUCTION 
The use of externally applied electrical energy to promote the healing of complex 
wounds is a concept that was introduced more than 40 years ago 1. There are various types 
of electrical stimulation (ES) devices but despite variation in application mode, dose and 
duration of therapy, the majority of trials show significant improvement in wound healing or 
wound area reduction compared to control treatment or standard care (reviewed by 2, 3). The 
use of continuous direct current of 200-800 μA and pulsed current  improved healing of chronic 
wounds in a number of studies 4-9. However, the mechanisms of ES-mediated wound healing 
in vivo are poorly understood with a number of different explanations provided for the clinical 
outcomes reported.  
A recent systematic review concluded that the ideal ES device needs to be non-
invasive, portable, cost-effective and provides minimal interference with patients’ daily life 3.  
In addition, a device that delivers a programme of fixed parameters and duration is important 
in order to standardise findings and to make comparisons and draw conclusions from studies 
or clinical applications that use it. The device used for this study is a class IIA medical device 
(under medical directive 93/42/EEC, which has full Medical Devices Directorate approval 
under ISO 13485:2003). The device delivers a proprietary frequency of pulsed electrical 
energy at the microcurrent level delivered directly to the skin via two off-the-shelf treatment 
electrode pads placed directly onto intact skin for a duration of 48 hours. Knowledge of the 
existence of ES-responsive genes might provide new potential lines of scientific enquiry for 
identifying similar gene responses in subjects with slow or poorly healing wounds.  
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CLINICAL PROBLEM ADDRESSED 
The identification of how ES can regulate or modify gene expression in skin is critical in 
improving the understanding of why ES treatment improves healing rates in chronic wounds 
in some individuals and not in others. If we could identify the ES-responsive genes it might be 
possible to measure the expression in responders and non-responders to predict treatment 
efficacy in different patient groups and to select ES treatment parameters that yield the best 
wound healing outcomes.
 
 
P
A
G
Lallyett et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
MATERIAL AND METHODS  
Study design and participants 
The study was an investigator-initiated, double-blinded, randomized, placebo-
controlled trial undertaken at Bispebjerg Hospital, Copenhagen, Denmark. The study was 
reported to the Danish register (Datatilsynet), and was performed in accordance with Danish 
law (Lov om behandling af personoplysninger). This included an approval from the Regional 
Ethical Committee for the Hospital Region of Greater Copenhagen (Region H) (H-3-2012-
158). Only healthy male Caucasians, aged 20-30 years old, a BMI of between 19 and 25, non-
smokers, no history of cancer, diabetes or vascular disease, and who undertook similar levels 
of moderate physical activity per week were recruited. Two ES devices identical in appearance 
(one active and one placebo) were attached to pairs of electrodes identical in appearance, 
were placed on intact healthy skin of opposite buttocks of 12 healthy male subjects. The 
electrode pads of each device were 10 cm apart and there was a 20 cm gap between the 
electrode pads of the different devices (Fig. S1B). Only a third independent person had 
knowledge of which device was active, thus the study was double-blinded. The placebo 
devices were identical in appearance and function to the activated devices. After 48 hours full-
thickness skin biopsies of 4-mm diameter were excised from a region midway between the 
two electrodes. 
 
Comparative microarray 
RNA was isolated from skin biopsies and cells using TRIzol reagent (Invitrogen) 
following manufacturers’ protocols as previously described10. RNA concentrations and 
integrity were measured using Agilent 2100 Bioanalyzer (Agilent Technologies). The RNA was 
amplified and hybridized to Human Genome U133 2.0 GeneChip arrays (Affymetrix). 
Microarray data are available in the ArrayExpress database under accession number E-
MTAB-3935. Technical quality control and outlier analysis was performed with dChip 
(V2005)11 using the default settings. Background correction, quantile normalization, and gene 
Lallyett et al. 
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expression analysis were performed using RMA in Bioconductor12. To assess if ES altered 
gene expression in the skin, an ANOVA linear model was employed to evaluate where the 
variation within the data set came from (Partek Genomics Solution version 6.5, Copyright 
2010, Partek Inc., St. Charles, MO, USA). Differential expression analysis was performed for 
subjects that were exposed to ES using a paired model in Limma using the functions lmFit 
and eBayes13. A gene list of differentially expressed genes was formed from probe sets that 
had >1.5-fold change, p<0.05. 
 
Data analysis 
Gene ontology analysis using DAVID (Database for Annotation, Visualization and 
Integrated Discovery) and Ingenuity Pathway Analysis (Qiagen) showed there is an 
enrichment of RAGE-binding proteins: S100A7, S100A8, and S100A9. A comparison was 
performed with wound-regulated genes in a microarray data set generated by Cooper et al. 14 
under the ArrayExpress accession number E-MTAB-383614 and with genes differentially 
regulated in venous leg ulcer (VLU) wound edge as described15. 
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RESULTS 
The study comprised of 12 participants, of which nine received one activated and one 
placebo ES device and three participants received only placebo devices (Fig. 1). The device 
delivered a series of pre-set programs in which there is varying amplitude (40-500 μA), 
frequency (10-900 Hz) and polarity (alternating every 0.1 seconds). The electrical pulses were 
delivered as repeated 240-minute treatment sessions with a two-hour resting period between 
each in the first 24 hours and a four-hour resting period between each in the second 24 hours 
(Fig. S1). RNA was isolated from full-thickness skin biopsies and analysed by microarray. 
Unbiased statistical analyses showed that one of the 24 samples was an outlier and was 
excluded from subsequent analyses (Fig. S2A). Both principal component analysis and linear 
model evaluation suggested that the largest source of variation in global gene expression 
changes was from differences between individuals (Fig. S2B). No significant differential 
expression was detected between biopsies from treatment with two placebo devices in any of 
the 3 control participants. A within-subject analysis of ES treated versus placebo treated skin 
produced a significant variation score of 1.47, as illustrated by the 15 most differentially 
regulated (Fig. S2C). Thus, alterations in levels of gene expression levels could be attributed 
to the 48-hour ES treatment. 
To accommodate the large variation due to individuals a paired test was used, resulting 
in 105 annotated genes which have significant differential regulation of 1.5-fold (p<0.05) in ES 
treated skin compared with placebo treatment (listed in Supplementary Table 1). A volcano 
plot of the microarray data shows that the majority of these differentially regulated genes were 
reduced in expression, with the exception of two genes (Fig. 2A). 
We subjected this list of ES regulated genes to unbiased functional annotation 
analyses using DAVID (Database for Annotation, Visualization and Integrated Discovery) and 
by IPA (Ingenuity Pathway Analysis). Functional gene ontology analysis showed that there 
was an overrepresentation of genes in particular cellular compartment, including focal 
adhesion (ANXA6, PDIA3, TPM4, LPP), protein-DNA complex (CTNNB1, HNRNPK, JUP), 
Lallyett et al. 
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and endoplasmic reticulum-Golgi intermediate compartment membrane (TMED9, RAB2A, 
ERGIC1), and in genes encoding ribonucleoprotein (TEP1, HNRNPH1, MRPS16, MRPL30), 
gene activators (SUPT4H1, SMARCA2, MAX, RORC, EBF1), and RAGE (receptor for 
advanced glycation end products)-binding proteins (S100A7, S100A8, S100A9) (see 
Supplementary Table 1). Pathway analysis showed that these ES-regulated genes were 
implicated in canonical pathways, including regulation of macrophages production of IL-12, 
nitric oxide and reactive oxygen species, and IL-17A in psoriasis (Fig. 2B). Next, we compared 
the list of ES regulated genes to two publically available sets of array data that identified genes 
regulated by wounding. First, we compared our data set to over 2600 probe sets differentially 
regulated 24 hours after wounding in vivo identified in a mouse skin injury model14. In common 
were 25 genes that were upregulated in wounding but downregulated with ES and one gene 
(RAD23B) was similarly downregulated in both microarray studies (see Table 1). Next, we 
compared the list of ES regulated genes to the top 50 most upregulated and top 50 most 
downregulated genes identified in the wound edge of venous leg ulcers (VLUs)15. All three 
S100 genes and SERPINB4 were upregulated in the VLU wound edge but were 
downregulated in ES-treated skin (see Table 1). 
 
DISCUSSION 
The primary finding of the current study is that ES delivered with a pre-set fixed 
programme and duration to healthy human skin reduces the expression of a specific set of 
genes that have been found to be upregulated in skin inflammation. This study used healthy 
volunteers instead of patients with chronic wounds primarily because of the risk of the biopsy 
procedure could have adverse effects on the healing of the wound.  We do not know from the 
results of this study, but can hypothesise, that the same ES device applied in the same manner 
would have the same effects on healthy wound edge skin adjacent to a chronic wound.  
However, many patients with chronic, poorly and non-healing wounds commonly present with 
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co-morbidities so this hypothesis would have to be fully tested and the results compared with 
the current study in order to draw a safe conclusion.  
The duration of the treatment of 48 hours was chosen to investigate any immediate 
differential gene expression because it is one application of the device’s full delivery cycle.  As 
the device was applied over the buttocks, we suggest that 48 hours was an acceptable length 
of time for participants to withhold from showering, bathing and activities that could cause 
excessive sweating. Analysis of the sources of variation reinforced the fact that there is 
extensive variation between participants, but did indicate that ES significantly affected the 
expression of specific genes. Whilst the variations of age, gender, smoking, activity levels and 
no medication were controlled for, other variations in the participants’ life style (e.g. activity 
and diet) or underlying medical conditions were unknown. However, the participants were all 
healthy young individuals without any signs of abnormal conditions or diseases. The 
participant profiles of the most regulated genes varied between participants, suggesting that 
some of the participants could be viewed as either responders or non-responders to the ES 
treatment. 
Functional annotation analysis of the 105 ES-regulated genes showed that there is an 
enrichment of RAGE-binding proteins: S100A7, S100A8, and S100A9. We were able to 
compare our findings with only two other publically available array data sets produced from 
wound-related studies 14, 15, however the comparisons confirmed that S100 genes were 
upregulated in both acute and chronic wounds. These proteins are expressed at low levels in 
keratinocytes in healthy skin but are upregulated upon wounding. The expression of S100 
genes has been shown to be crucial for re-epithelialization of the wound16, recruitment of 
inflammatory cells17, 18, and regeneration of the hair follicle19, and regulating keratinocyte 
growth and differentiation20, which can promote wound healing. Controversially, S100 proteins 
are also readily detected in wound exudates21, 22, upregulated in chronic wounds15, 23 and 
psoriasis24, 25, which suggest their expression is a biomarker for non-healing wounds. 
Overexpression of S100 genes in HaCat keratinocytes impaired collective migration in the cell 
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sheet immediately behind the migrating front in an in vitro scratch wound assay, and staining 
of β-catenin showed cells adjacent to gaps in the cell sheet had no positive staining in the 
periphery but accumulated cell junction proteins in the cytosol when S100 genes were over 
expressed (data not shown). 
It is thought that a prolonged inflammatory phase and the increased expression of 
proteolytic enzymes prevent wounds from progressing into the proliferative phase, and are 
major factors that contribute to wounds becoming non-healing26. Pathway analysis indicated 
that the ES application dampened the release of pro-inflammatory cytokine interleukin-12, 
nitric oxide and reactive oxygen species by macrophages known to be responsible for the 
breakdown of connective tissues (reviewed by27). Reduction of S100A7, S100A8, and S100A8 
and activation of macrophages by ES could potentially improve wound healing by dampening 
these pathways in chronic wounds. 
In summary, for future studies it could be hypothesized that ES mediated healing of 
chronic wounds could be achieved via down-regulation of certain gene pathways that are 
known to compromise wound healing and which are upregulated in skin wounds, thus enabling 
an improved rate of wound repair. 
 
Limitations of the study 
This study was performed on a small number of participants. We cannot make an inference 
from this study that if the same ES device was applied in the same manner to the periwound 
skin of a poorly healing wound it would have the same effect as on skin of healthy volunteers. 
Patients with chronic, poorly and non-healing wounds commonly present with co-morbidities 
so this hypothesis would have to be fully tested and the results compared with the current 
study with larger subject numbers with different wound types in order to draw a safe 
conclusion. There are no known or anticipated or known side effects from this electroceutical 
application. The product used is CE marked for safety and is accredited as a Class IIA medical 
device under the directorate ISO13485. 
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A single type of ES device was used for this investigation delivering a fixed pulse 
sequence and duration of ES. Therefore, we do not know if the same changes in gene 
expression reported here would be seen if a different set of ES parameters were used. 
 
Further areas of study 
The identification of the changes in gene expression, albeit in healthy skin provide potential 
novel therapeutic targets for the development of a treatment for individuals who present with 
delayed skin healing. However, this study used the skin on the buttocks of healthy individuals 
so findings may be different in different areas of the body where skin thickness varies.  
Therefore, this too would have to be ruled out as a significant variant. 
Identifying higher levels of these proteins may help to identify the patients in this group 
who are likely to have healing problems.   However, as a single type of ES device was used 
for this investigation delivering a fixed frequency of pulsed electrical energy and duration of 
ES further investigation is required to see if the same changes in gene expression are caused 
using a different set of ES parameters. The UK’s National Health Service (NHS) managed an 
estimated 2.2 million patients with a wound during 2012/2013, equivalent to 4.5% of the adult 
population 28. The annual cost to the NHS attributable to wound management and associated 
comorbidities was estimated at £5.3 billion28. Our study is a first step towards a mechanistic 
understanding of the potential benefits of electrical stimulation for improving skin healing in 
pathological conditions. 
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INNOVATION 
This study provided an insight and a line of further investigation into a possible mechanism by 
which ES improves the rate of healing in poorly healing wounds, whereby genes upregulated 
during inflammation in wounds are inactivated by the ES application. We identified 105 genes 
in skin that are regulated, most of which were downregulated, by application of ES for 48 
hours. The identification of these genes, albeit in healthy skin, provides potential novel 
therapeutic targets for the development of a treatment for individuals who present with delayed 
skin healing.  Identifying higher levels of these proteins may help to identify the patients in this 
group who are likely to have healing problems. 
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KEY FINDINGS 
 A defined and set programme of electrical stimulation (ES), delivered to the skin 
regulates 105 genes in the skin, the majority of which are downregulated by the 
treatment. 
 Our post-microarray analyses revealed there was commonality with genes that have 
previously been shown to be upregulated in complex wounds in skin. 
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ABBREVIATIONS AND ACRONYMS 
ES electrical stimulation 
VLU venous leg ulcer 
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TABLES 
Table 1. List of genes common with those differentially regulated in skin 24 hours post 
wounding and in VLU wound edge. 
 
Gene Symbol  ES device  Acute wound  VLU wound edge 
   vs. placebo  vs. control  vs. control 
   (fold change)  (fold change)  (fold change)15 
SERPINB4  -3.62   -   94.96 
S100A7  -3.37   -   105.80 
EIF5A   -2.52   1.62   - 
S100A8  -2.26   90.42   95.11 
A02B1   -2.24   1.47   - 
PDAP1  -2.17   1.52   - 
S100A9  -2.16   97.95   119.00 
LYZ   -2.14   1.24   - 
SET   -2.09   1.48   - 
VCAN   -1.98   8.59   - 
CPR124  -1.93   2.72   - 
CD47   -1.92   1.60   - 
RAD23B  -1.92   -1.26   - 
SPP1   -1.90   7.52   - 
CALD1  -1.88   1.52   - 
ARPC4  -1.87   1.77   - 
LCN2   -1.81   44.12   - 
PDIA3   -1.67   1.56   - 
ERGIC1  -1.67   1.70   - 
RNF125  -1.66   1.27   - 
KRT17   -1.64   2.72   - 
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KRT6B  -1.63   146.32   37.66 
APP   -1.62   -   -9.17 
TPM4   -1.55   1.70   - 
RBM3   -1.53   1.53   - 
SOX7   -1.53   1.23   - 
GNB4   -1.52   1.51   - 
AQP3   -1.52   2.80   - 
GNG12  -1.50   1.36   -
Lallyett et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
FIGURE LEGENDS 
Figure 1. Flow chart of study to identify genes in skin that are regulated by ES. 
 
Figure 2. ES treatment to healthy skin leads to downregulation of gene expression. 
(A) Volcano box plot to illustrate the expression changes of all genes. The 105 genes whose 
expression was significantly altered ≥1.5-folds, p<0.05 are shown in the top left and top right 
boxes. (B) Top 10 canonical pathways identified in ES-regulated genes in skin by Ingenuity 
Pathway Analysis. 
 
Table 1. Genes common with those differentially regulated in skin 24 hours post wounding 
and in VLU wound edge. 
 
Supplementary Figure 1. ES application to skin of healthy participants. 
(A) The ES device. (B) Two ES devices were applied to the skin overlying the buttocks (one 
on each side). The electrode pads of each device were 10 cm apart and there was a 20 cm 
gap between the electrode pads of the different devices. (C) Program specification of the ES 
device.  
 
Supplementary Figure S2. Variation between individuals.  
(A) D-chip analysis of samples obtained from the 12 participants of the study. *Warning for 
sample from participant 8’s ES treatment as an array outlier, which was subsequently 
excluded from further analyses. (B) Principal component analysis (PCA) was used to provide 
a statistical summary of the array samples, and the first three principal components are shown. 
C = control; MC = microcurrent (ES). (C) The top 15 differentially regulated genes (as ranked 
by fold change) of the 8 participants who were treated with a placebo and the ES device. Note 
that SERPINB4 expression in participant 1 is not included in the graph but it showed a fold 
change of over -90 with ES treatment. 
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Supplementary Table 1. List of 105 genes in skin regulated differentially by 48 hours of 
treatment with the ES device. 
Supplementary Table 2. Annotation clusters of genes differentially regulated by an externally 
applied electrical stimulation on healthy skin. 
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